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Abstract
Migraine is a largely inherited disorder of the brain characterized by a complex, but stereotypical,
dysfunction of sensory processing. Often the most obvious clinical symptom is head pain, but non-
headache symptoms such as photophobia, phonophobia and nausea are clearly part of the typical
presentation. This review discusses the current pathophysiological concepts of migraine and
migraine aura, such as a possible brainstem dysfunction and cortical spreading depression. Acute
and preventive migraine treatment approaches are briefly covered with a focus on shortcomings of
the currently available treatment options. A number of different receptors, such as calcitonin gene-
related peptide (CGRP), TRPV1 and glutamate receptors, are currently being targeted by potential
novel migraine therapeutics. The prospects of this research are exciting and are likely to improve
patient care.
Introduction
Migraine is a disorder characterized by a broad sensory
processing dysfunction. Thereby, the perception of nor-
mal sensory stimuli, somatosensory, visual, auditory and
olfactory, is thought to be centrally facilitated. This dys-
function has a strong genetic background [1] and leads to
the perception of a combination of headache, photopho-
bia, phonophobia, osmophobia and nausea. The disorder
was considered to be vascular in origin for much of the
20th century [2], although it was considered to be a disor-
der of the nervous system by 19th century luminaries [3].
This was related to the pounding or throbbing nature of
the pain and triggering by vasoactive substances that now
seem more likely to be due to the prominent perception
of pain in the context of the dense somatosensory inner-
vation of intracranial vessels. This view is supported by
data which include the fact that: vasoactive intestinal pep-
tide - a strong intracranial vasodilator - does not trigger
migraine [4]; intracranial vasodilatation also occurs sec-
ondary to experimental head pain stimulation [5], proba-
bly mediated by the trigeminal-parasympathetic reflex;
and non-vasoconstrictor drugs, such as aspirin [6] and cal-
citonin gene-related peptide (CGRP) receptor antagonists
can abort migraine attacks [7]. Most importantly, head-
ache is only one of the neurological symptoms of
migraine, where the dysfunction can really only be
located in the brain itself.
This article provides an update on potential mechanisms
of migraine and aura pathogenesis and reviews current
and future medical strategies for the acute and preventive
treatment of migraine.
Aura and cortical spreading depression
A subgroup of migraineurs experience aura, typically
before the onset of head pain, with some of their attacks
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and there are several lines of evidence that cortical spread-
ing depression is the pathophysiological substrate. In
early clinical observations, it was noted that the progres-
sion of aura symptoms is consistent with a process tran-
siently compromising cortical function at a speed of about
3 mm per minute [8]. Leao suggested that cortical spread-
ing depression (CSD), advancing at the identical speed
over the cortex, was the electrophysiological correlate of
visual aura in humans. By now, the existence of CSD in
humans has been proven using electrophysiological
methods [9-11] and human imaging studies [12,13]. A
possible link between CSD and headache has been pro-
vided by the observation that CSD can activate trigeminal
meningeal afferents [14], although contradictory data also
exist [15]. Hence, CSD could not only induce aura symp-
toms, but also explain the head pain in patients with aura.
This view is not supported by recent controlled trials
which show that tonabersat, a possible gap-junction
blocker and inhibitor of CSD [16], does not prevent
migraine headache [17] but can prevent migraine aura
[18]. It has been suggested that CSD also has a role in
migraine without aura but the tonabersat studies suggest
this is less likely. Silent aura, the occurrence of CSD con-
fined to regions not clinically eloquent and still activating
trigeminal afferents, is a tempting concept when looking
for a unifying concept of migraine with and without aura.
However, as noted above in the study by Hauge et al. [18],
tonabersat was ineffective in migraine without aura and,
as the drug reduced the frequency of aura attacks, this
result clearly challenges the concept of the silent aura [18].
Moreover, in a recent case series, three patients were
described who reported that their auras resolved when
migraine preventives were started, while in parallel they
experienced a worsening of the frequency of their
migrainous headaches [19]. Finally, the sequence of a
migraine attack has probably already been initiated long
before the actual onset of CSD and aura. Migraine attacks
often start with a typical premonitory phase when patients
complain of tiredness, reduced concentration, irritability,
yawning and other non-headache symptoms hours to
days before the onset of aura and headache [20,21]. At
this point, many patients can predict the onset of a full-
blown migraine attack and the start with non-headache
symptoms underlines that migraine is much more than an
isolated pain disorder.
Neurogenic plasma protein extravasation
It has been suggested that some component of the
migrainous pain is related to dural plasma protein
extravasation with sterile neurogenic inflammation [22].
Electrical stimulation of the trigeminal ganglion induces
plasma protein extravasation and this can be blocked by
some of the substances which are active in acute migraine
attacks (for example, sumatriptan) [23]. On the other
hand, a blockade of neurogenic plasma protein extravasa-
tion is not completely predictive of anti-migraine efficacy,
as other compounds which are effective in this experimen-
tal model of migraine, such as neurokinin-1 receptor
antagonists, have failed in clinical migraine prevention
trials [24,25]. Hence, plasma protein extravasation seems
to be an epiphenomenon rather than a pivotal mecha-
nism of trigeminal activation and migraine generation
[26].
Brainstem dysfunction in migraine 
pathogenesis?
In our view, the whole clinical picture of migraine can be
better explained by a dysfunction of neuromodulatory
structures in the brainstem, such as the locus coeruleus or
periaqueductal grey matter. The locus coeruleus, the
major noradrenergic nucleus, has a critical role in the reg-
ulation of cortical function and is known to modulate
responses to afferent traffic [27]. Its connections are
widely distributed throughout the neocortex and in posi-
tron emission tomography (PET) studies investigating
acute migraine attacks, activation of an area of the dorso-
lateral brainstem that included the locus coeruleus has
been shown [28,29], although there is some remaining
uncertainty regarding the exact anatomical location of this
activation because of the limited spatial resolution of PET.
Compared to other hypothesis on migraine neurobiology,
dysfunction of such brainstem structures and networks
could not only account for the somatosensory component
of migraine (headache) but also for the auditory, olfactory
and visual components. Moreover, a locus coeruleus dys-
function could also explain the distractibility and anxiety
[27] which is often observed in migraineurs.
Pharmacological and interventional strategies of 
migraine prevention
Migraine prevention is an important component of ther-
apy aimed at reducing the attack frequency and severity.
Unfortunately, the mechanisms of action of current pre-
ventives are not well understood. A potential mechanism
is the inhibition of cortical spreading depression but, as
noted above, the efficacy against cortical spreading
depression does not necessarily predict the efficacy in
treating migraine without aura [18]. Substances that have
proven beneficial in migraine, with and without aura,
broadly comprise compounds from the following classes:
beta-blockers (for example, propranolol), antidepressants
(for example, amitriptyline), anticonvulsants (for exam-
ple, valproate, topiramate), calcium channel blockers (for
example, flunarizine) and serotonin antagonists (for
example, methysergide) [30]. According to the patho-
physiological concepts discussed above, these drugs most
probably target the activity of modulatory circuits as well
as the neuronal activity in afferent sensory pathways such
as the trigeminal system [31]. Although many patients can
be effectively managed using the available substances,BMC Medicine 2009, 7:71 http://www.biomedcentral.com/1741-7015/7/71
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side effects and contraindications because of co-morbidi-
ties can complicate treatment. A particular problem is the
prediction of which patients will respond to which sub-
stance as treatment is often largely conducted by trial and
error, which is frustrating for the patients and treating
physicians alike. In order to obtain a better understanding
of the mechanisms of the action of the available sub-
stances, phenotype-driven treatment approaches [32] as
well as pharmacogenomic considerations [33], might
help to overcome such issues. Moreover, newer treatment
strategies, such as the use of Botulinum toxin in migraine
prevention, are currently undergoing clinical trials (Table
1). Interventional neuromodulational approaches are
also promising, including the stimulation of the occipital
nerve, where functional imaging studies show that the
central processing of pain signals in migraine in the thala-
mus may be modified by such therapies [34]. Studies,
such as ONSTIM [35] and PRISM [36], are now complete
with their implications being analysed (PRISM
NCT00286078 and [37-39]). This exciting and develop-
ing area might be especially helpful in the treatment of
medically refractory patients.
Pharmacological strategies for migraine attack 
treatment
Treatments for acute attacks can be divided into non-spe-
cific anti-pain compounds, such as simple analgesics and
NSAIDS, and more migraine-specific treatment
Table 1: Selected migraine drug development programs (compiled from http://www.clinicaltrials.gov).
Drug Mechanism of action Stage of development
Acute attack
Telcagepant (MK-0974) CGRP receptor antagonist Phase III- complete
BI 44370 CGRP receptor antagonist Phase II
COL-144 5-HT1F receptor agonists Phase II
SB-705498 TRPV1 receptor antagonists Phase II
BGG492 AMPA receptor antagonist Phase II
Tezampanel (LY-293558) AMPA and kainate receptor antagonist Phase II
LY466195 GLUK5 kainate receptor antagonists Phase II
NPS 1776 Anticonvulsant Phase II
BGC20-1531 Prostanoid EP4 receptor antagonist Phase II
NXN-188 nNOS inhibition and 5-HT1B/D agonist Phase II
Preventives
Ramelteon Melatonin MT1 and MT2 receptor agonist Phase IV
Botulinum Toxin type A Unknown Phase III
Tonabersat Gap junction/CSD inhibitor Phase II- failed in migraine without aura
ADX10059 mGluR5 Modulator Phase II
Perampanel (E2007) AMPA receptor antagonist Phase II
GW274150 iNOS Phase II- failed
Carisbamate (RWJ-333369) Anticonvulsant Phase II- failed
CGRP, calcitonin gene-related peptide; CSD, cortical spreading depression; nNOS, nitric oxide synthase; iNOS, inducible nitric oxide synthaseBMC Medicine 2009, 7:71 http://www.biomedcentral.com/1741-7015/7/71
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approaches, such as ergot-derivates and triptans, which
are active at 5-HT1 receptors. Stratified care, the choice of
an acute medication on the basis of attack characteristics,
has been shown to be superior to stepped care [40] and,
as triptans are most effective, a triptan is typically chosen
for the more severe migraine attacks. Triptans, because of
their better tolerability, have replaced ergotamine in most
cases [41]. Sumatriptan and its six licensed successors are
agonists at 5HT1B/D receptors. They reduce neuronal activ-
ity via these receptors at the trigeminocervical complex
[42] and thalamic level [43] and these areas, instead of the
blood vessels, are most probably also important sites for
their therapeutic action in migraine. There are still situa-
tions where tolerability and contraindications to use are a
problem. The main issue for triptans relates to their vaso-
constrictor properties and related cardiovascular and cere-
brovascular safety concerns. This necessitates that triptans
are not used in patients with cerebrovascular or cardiovas-
cular contraindications [44]. The new group of so-called
Gepants, CGRP receptor antagonists, may soon offer an
option to such patients. Two substances of this class,
parenteral olcegepant [7] and oral telcagepant [45], have
proved to be effective in the acute treatment of migraine
without vascular liability [46]. Their effectiveness seems to
be comparable to triptans [45].
The announcement of the success of a phase II dose-rang-
ing proof-of-concept study with the 5-HT1F receptor ago-
nist CO-144 offers another prospect for a non-
vasoconstrictor acute anti-migraine therapy [47]. The suc-
cess of CGRP receptor antagonists and 5-HT1F receptor
agonists reinforce a neurally-based approach to migraine
and emphasize that migraine is a brain disorder. Other
strategies, such as nitric oxide synthase inhibitors [48],
vanilloid TRPV1 receptor antagonists [NCT00269022,
[49]] and glutamate, AMPA/kainate receptor [50] as well
as pure kainate receptor antagonists, will hopefully follow
providing an even broader repertoire of migraine-specific
drugs (Table 1, [16,51]).
Conclusion
Migraine is a disorder of the brain characterized by a com-
plex sensory dysfunction. Hence, therapeutic approaches
with neural targets are most promising. Currently, a
number of such pharmacological and interventional ther-
apies are being investigated and it is likely that patients
can benefit from CGRP receptor antagonists and occipital
nerve stimulation in the near future. In addition to these
new treatment strategies, defining patient populations
who are more likely to respond to the already available
therapeutic options also has great potential to improve
patient care in daily practice.
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